Spots Global Cancer Trial Database for obatoclax mesylate
Every month we try and update this database with for obatoclax mesylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | NCT00538187 | Adult Non-Hodgk... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... | obatoclax mesyl... bortezomib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | NCT00612612 | B-cell Chronic ... Leukemia Prolymphocytic ... Refractory Chro... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | obatoclax mesyl... fludarabine pho... rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | NCT00407303 | Mantle-Cell Lym... | Obatoclax mesyl... Bortezomib | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00719901 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | obatoclax mesyl... bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01238146 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... | bendamustine hy... obatoclax mesyl... rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Obatoclax for Systemic Mastocytosis | NCT00918931 | Leukemia Systemic Mastoc... | Obatoclax Mesyl... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | NCT00407303 | Mantle-Cell Lym... | Obatoclax mesyl... Bortezomib | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) | NCT00427856 | Lymphoma, Folli... | Obatoclax mesyl... Rituximab | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00719901 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | obatoclax mesyl... bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma | NCT00724841 | Metastatic Mela... | Obatoclax Mesyl... Temozolomide | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | NCT00521144 | Recurrent Small... Unspecified Adu... | obatoclax mesyl... topotecan hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | NCT00521144 | Recurrent Small... Unspecified Adu... | obatoclax mesyl... topotecan hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
